$STEK
Stemtech Corp Stock $stek

$stek Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000168316823003420 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q1
Revenue	$1.133M	$1.080M	$1.156M
YoY Change	-1.99%	-17.74%
Cost Of Revenue	$244.8K	$327.6K	$262.6K
YoY Change	-6.77%	-26.78%
Gross Profit	$888.5K	$752.0K	$893.7K
YoY Change	-0.58%	-13.07%
Gross Profit Margin	78.4%	69.66%	77.29%
Selling, General & Admin	$1.818M	$898.2K	$912.3K
YoY Change	99.23%	-56.11%	20681.78%
% of Gross Profit	204.57%	119.44%	102.08%
Research & Development	$13.80K		$0.00
YoY Change
% of Gross Profit	1.55%		0.0%
Depreciation & Amortization	$119.6K	$117.2K	$107.1K
YoY Change	11.65%	12.32%
% of Gross Profit	13.46%	15.59%	11.99%
Operating Expenses	$2.140M	$1.184M	$1.074M
YoY Change	99.17%	-55.91%	24369.93%
Operating Profit	-$1.251M	-$432.2K	-$180.5K
YoY Change	593.0%	-76.27%
Interest Expense	-$1.489M	-$204.2K	-$327.9K
YoY Change	354.1%	-119.3%	7650.83%
% of Operating Profit
Other Income/Expense, Net	-$1.021M	$600.00	-$1.020K
YoY Change	100035.39%	-100.71%
Pretax Income	-$2.272M	-$446.1K	-$509.4K
YoY Change	346.09%	-47.4%	5809.51%
Income Tax	-$35.42K	$95.62K
% Of Pretax Income
Net Earnings	-$2.237M	-$518.9K	-$494.7K
YoY Change	352.1%	-38.19%	5639.44%
Net Earnings / Revenue	-197.36%	-48.06%	-42.79%
Basic Earnings Per Share	-$0.04		-$0.01
Diluted Earnings Per Share	-$0.04	-$0.01	-$11.07K
COMMON SHARES
Basic Shares Outstanding	58.31M shares	48.63M shares	44.69M shares
Diluted Shares Outstanding	58.31M shares		44.69M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$343.3K	$132.5K	$511.2K
YoY Change	-32.85%	-84.0%	189233.33%
Cash & Equivalents	$343.3K	$132.5K	$511.2K
Short-Term Investments
Other Short-Term Assets	$285.9K	$287.1K	$244.7K
YoY Change	16.82%	-11.59%	236.51%
Inventory	$109.1K	$158.1K	$283.8K
Prepaid Expenses
Receivables	$12.54K	$34.77K	$15.21K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$750.8K	$612.4K	$1.055M
YoY Change	-28.83%	-61.73%	1345.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.41K	$27.30K	$273.5K
YoY Change	-90.34%	-17.7%
Goodwill	$467.4K	$467.4K
YoY Change		0.0%
Intangibles	$3.162M	$2.994M
YoY Change		-12.11%
Long-Term Investments	$23.42K	$23.07K	$30.46K
YoY Change	-23.11%	-40.37%
Other Assets
YoY Change
Total Long-Term Assets	$3.806M	$3.655M	$4.074M
YoY Change	-6.57%	-11.3%
TOTAL ASSETS
Total Short-Term Assets	$750.8K	$612.4K	$1.055M
Total Long-Term Assets	$3.806M	$3.655M	$4.074M
Total Assets	$4.557M	$4.267M	$5.129M
YoY Change	-11.14%	-25.4%	6926.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.445M	$3.397M	$3.777M
YoY Change	-8.79%	-16.15%
Accrued Expenses	$108.4K	$119.1K	$80.62K
YoY Change	34.43%	113.58%
Deferred Revenue
YoY Change
Short-Term Debt	$1.108M	$1.143M	$1.621M
YoY Change	-31.66%	8.28%	431.22%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.256M	$7.416M	$9.505M
YoY Change	-2.62%	-21.0%	2992.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$77.64K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$13.84K	$23.07K	$157.4K
YoY Change	-91.21%	-80.62%
Total Long-Term Liabilities	$13.84K	$23.07K	$235.0K
YoY Change	-94.11%	-93.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.256M	$7.416M	$9.505M
Total Long-Term Liabilities	$13.84K	$23.07K	$235.0K
Total Liabilities	$9.270M	$7.439M	$9.076M
YoY Change	2.14%	-23.51%	2852.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$23.87M	-$21.63M
YoY Change		65.3%
Common Stock	$61.14K	$19.44M
YoY Change		91.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.975M	-$2.434M	-$3.947M
YoY Change
Total Liabilities & Shareholders Equity	$4.557M	$4.267M	$5.129M
YoY Change	-11.14%	-25.4%	6926.36%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.237M	-$518.9K	-$494.7K
YoY Change	352.1%	-38.19%	5639.44%
Depreciation, Depletion And Amortization	$119.6K	$117.2K	$107.1K
YoY Change	11.65%	12.32%
Cash From Operating Activities	-$574.7K	-$240.8K	-$80.92K
YoY Change	610.17%	-77.5%	578.29%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	$0.00		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$798.6K	-176.0K	-30.84K
YoY Change	-2689.49%	-133.56%	-408.4%
NET CHANGE
Cash From Operating Activities	-$574.7K	-240.8K	-80.92K
Cash From Investing Activities	$0.00		$0.00
Cash From Financing Activities	$798.6K	-176.0K	-30.84K
Net Change In Cash	$210.8K	-416.8K	-111.8K
YoY Change	-288.62%	-23.8%	5690.67%
FREE CASH FLOW
Cash From Operating Activities	-$574.7K	-$240.8K	-$80.92K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001511820
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	333-172172
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	STEMTECH CORPORATION
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2151440
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	10370 USA Today Way
CY2023Q1	STEK	Factoring Liability FactoringLiability	78247	usd
CY2022Q4	STEK	Factoring Liability FactoringLiability	214249	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4519536	usd
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Miramar
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33025
CY2023Q1	dei	City Area Code CityAreaCode	(954)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	715-6000
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	64739899	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	343291	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132487	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	12535	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	34767	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	109143	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	158053	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	285860	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	287063	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	750829	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	612370	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26410	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27296	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3162413	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2994000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	23416	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	23065	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	126526	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	142801	usd
CY2023Q1	us-gaap	Goodwill Goodwill	467409	usd
CY2022Q4	us-gaap	Goodwill Goodwill	467409	usd
CY2023Q1	us-gaap	Assets Assets	4557003	usd
CY2022Q4	us-gaap	Assets Assets	4266941	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3444987	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3396543	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	289949	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	446246	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	739315	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	482885	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108376	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	119065	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	75907	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	39170	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2717633	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9256317	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7415791	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13836	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23068	usd
CY2023Q1	us-gaap	Liabilities Liabilities	9270153	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7438859	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61136808	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61136808	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53442147	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53442147	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	61137	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	53442	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20092577	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19391400	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-260890	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-247760	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23867971	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21631241	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3975147	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2434159	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	-738003	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-737759	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4713150	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3171918	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4557003	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4266941	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1133341	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1156308	usd
CY2023Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	231817	usd
CY2022Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	246226	usd
CY2023Q1	STEK	Freight In Costs FreightInCosts	13000	usd
CY2022Q1	STEK	Freight In Costs FreightInCosts	16371	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	244817	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	262597	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	888524	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	893711	usd
CY2023Q1	STEK	Commission Expenses CommissionExpenses	308087	usd
CY2022Q1	STEK	Commission Expenses CommissionExpenses	161912	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	133387	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	140309	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1684260	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	772012	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13800	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2139534	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	1074233	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1251010	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-180522	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	1881166	usd
CY2022Q1	us-gaap	Interest Expense Other InterestExpenseOther	525366	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	392355	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	197510	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	468678	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1248	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1024	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1021381	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-328880	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2272391	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-509402	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-35417	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2236974	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-509402	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-244	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14662	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2236730	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-494740	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58307347	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44685673	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58307347	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44685673	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2236730	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-494740	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	13130	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	205253	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2249860	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-699993	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	108260	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-205253	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14662	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-494740	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4611841	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3171918	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	108260	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	65354	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	263338	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	271920	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-13130	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-244	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2236730	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4713150	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2236974	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-509402	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	119598	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	107120	usd
CY2023Q1	STEK	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	16275	usd
CY2022Q1	STEK	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	-9454	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-19921	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	8474	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	108260	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	108260	usd
CY2023Q1	STEK	Noncash Interest Expense From Issuance On Debt Derivative NoncashInterestExpenseFromIssuanceOnDebtDerivative	1512936	usd
CY2022Q1	STEK	Noncash Interest Expense From Issuance On Debt Derivative NoncashInterestExpenseFromIssuanceOnDebtDerivative	0	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	381211	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	453805	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	392355	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	197510	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	468678	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	65354	usd
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-22232	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4488	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-48910	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-152590	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1203	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-80002	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	230897	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-278543	usd
CY2023Q1	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	351	usd
CY2022Q1	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-8229	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	36737	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-574666	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-80917	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	usd
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023Q1	STEK	Payments On Factoring Arrangements PaymentsOnFactoringArrangements	194954	usd
CY2022Q1	STEK	Payments On Factoring Arrangements PaymentsOnFactoringArrangements	-0	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6446	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	30835	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	798600	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-30835	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-13130	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-205253	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	210804	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-317005	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132487	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	828206	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	343291	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	511201	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	3013	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	STEK	Stock Issued For Lfr Acquisition StockIssuedForLfrAcquisition	271920	usd
CY2022Q1	STEK	Stock Issued For Lfr Acquisition StockIssuedForLfrAcquisition	0	usd
CY2023Q1	STEK	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt	263338	usd
CY2022Q1	STEK	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt	0	usd
CY2023Q1	STEK	Recognition Of Right Of Use Asset Operating Lease RecognitionOfRightOfUseAssetOperatingLease	0	usd
CY2022Q1	STEK	Recognition Of Right Of Use Asset Operating Lease RecognitionOfRightOfUseAssetOperatingLease	53463	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_809_eus-gaap--NatureOfOperations_zRo7xDfMB9l6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_824_z1vAJ3cOvA06">Organization and Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stemtech Corporation and its Subsidiaries (collectively, the “<b>Company</b>”) was incorporated in the State of Nevada, USA on September 4, 2009 under the previous name Globe Net Wireless Corp. On November 19, 2021, the Company adopted an Amendment to its Articles changing the name of the Corporation to Stemtech Corporation in the state of Nevada, and on April 14, 2022, FINRA gave final approval for said name change, as evidenced by the 8-K filed that date. Stemtech is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in stem cell science, and believes it can demonstrate that adult stem cells function as the natural renewal system of the body. The Company believes our products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. Our mission is to enhance wellness and prosperity around the world. These products are marketed internationally by the Company’s subsidiaries and through independent distributors. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, OraStem® (Oral Health Care), and D-Fuze™ (Electromagnetic Frequency Blocker). Cellect One™ Rapid Renew Stem Cell Peptide Night Cream.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2021, Stemtech Corporation (“<b>Stemtech</b>”), a Delaware corporation, entered into a Merger Agreement (the “<b>Merger Agreement</b>”) with Globe Net Wireless Corp. (“<b>Globe Net</b>” or “<b>GNTW</b>”). The merger was accounted for as a reverse acquisition and recapitalization in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, <i>Business Combinations</i>. Management evaluated the guidance contained in ASC 805 with respect to the identification of the acquirer in the merger and concluded, based on a consideration of the pertinent facts and circumstances, that Stemtech acquired Globe Net for financial accounting purposes. On November 9, 2021, the Company changed its fiscal year end from a fiscal year end of August 31 to a calendar year end of December 31.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Stemtech (Parent) and its ten (10) subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: left; width: 4%">1)</td> <td style="text-align: left; width: 96%">Stemtech HealthSciences Corp (U.S.A.) (“Stemtech HealthSciences”) – 100%</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">2)</td> <td style="text-align: left">Stemtech Canada, Inc. (“Canada”) – 100%</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">3)</td> <td style="text-align: left">Stemtech Health Sciences S. de R.L. de C.V. (“Mexico”) – 100%</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">4)</td> <td style="text-align: left">Stemtech Services SARL de C.V. (Mexico) (“Stemtech Mexico”) – 100%</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">5)</td> <td style="text-align: left">Stemtech Malaysia Holdings Sdn. Bhd. (“Malaysia Holdings”) – 100%</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">6)</td> <td style="text-align: left">Stemtech Malaysia Sdn. Bhd. (“Malaysia”) – 70%</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">7)</td> <td style="text-align: left">Stemtech Taiwan Holding, Inc. (“Taiwan”) – 100%</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">8)</td> <td style="text-align: left">Tecrecel S.A. (“Ecuador”) – 100%</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">9)</td> <td style="text-align: left">Food & Health Tech Foodhealth SA (“Ecuador FHTFH”) – 100%</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">10)</td> <td style="text-align: left">Life Factor Research (“LFR”) – 100%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"> </p>
CY2023Q1	STEK	Working Capital WorkingCapital	-8500000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_z39d2Y5vxmm" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_869_zdAMW3Pfqip8">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	72985	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	103297	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	36158	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	54756	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	109143	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	158053	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11275341	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3836000	shares
CY2018Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2000000	shares
CY2018Q2	us-gaap	Bankruptcy Claims Amount Paid To Settle Claims BankruptcyClaimsAmountPaidToSettleClaims	400000	usd
CY2018Q2	STEK	Percentage Of Issued And Outstanding PercentageOfIssuedAndOutstanding	1	pure
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2036912	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1918200	usd
CY2023Q1	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	3162413	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	2994000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	18220	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	18220	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M26D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	109639	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	21890	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	131529	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9318	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	122211	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	1029264	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	929131	usd
CY2023Q1	STEK	Disbursement Decription DisbursementDecription	(i) the first disbursement in the amount of $1,000,000 occurred on March 27, 2023; (ii) the second disbursement in the amount of $200,000 is due within three (3) days after the filing of an S-1 registration statement; (iii) the third disbursement in the amount of $500,000 is due forty-five (45) days after effectiveness of an S-1 registration statement; and (iv) $120,000 is due forty-five (45) days after the third disbursement.
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	739315	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	482885	usd
CY2021Q4	STEK	Derivative Liabilities1 DerivativeLiabilities1	4224585	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	5366289	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	-10096512	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	3223271	usd
CY2022Q4	STEK	Derivative Liabilities1 DerivativeLiabilities1	2717633	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	2512936	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	-318678	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-392355	usd
CY2023Q1	STEK	Derivative Liabilities1 DerivativeLiabilities1	4519536	usd
CY2022	STEK	Proceeds From Factoring Liability ProceedsFromFactoringLiability	528984	usd
CY2023Q1	STEK	Proceeds From Factoring Liability ProceedsFromFactoringLiability	571500	usd
CY2023Q1	STEK	Cash Received For Future Receivables CashReceivedForFutureReceivables	449000	usd
CY2023Q1	STEK	Factoring Liability Gross FactoringLiabilityGross	113515	usd
CY2022Q4	STEK	Factoring Liability Gross FactoringLiabilityGross	292636	usd
CY2023Q1	STEK	Factoring Liability Discount FactoringLiabilityDiscount	35268	usd
CY2022Q4	STEK	Factoring Liability Discount FactoringLiabilityDiscount	78387	usd
CY2018Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	150000	usd
CY2019Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	267000	usd
CY2023Q1	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	267000	usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	267000	usd

Files In Submission

Name	View Source	Status
stek-20230331_def.xml	Edgar Link	unprocessable
stek-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001683168-23-003420-index-headers.html	Edgar Link	pending
0001683168-23-003420-index.html	Edgar Link	pending
0001683168-23-003420.txt	Edgar Link	pending
0001683168-23-003420-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stek-20230331.xsd	Edgar Link	pending
stek-20230331_pre.xml	Edgar Link	unprocessable
stemtech_ex3101.htm	Edgar Link	pending
stemtech_ex3102.htm	Edgar Link	pending
stemtech_ex3201.htm	Edgar Link	pending
stemtech_ex3202.htm	Edgar Link	pending
stemtech_i10q-033123.htm	Edgar Link	pending
stemtech_i10q-033123_htm.xml	Edgar Link	completed
stek-20230331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STEK
Stemtech Corp Stock $stek

2023 Q1 Form 10-Q Financial Statement

#000168316823003420 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK Stemtech Corp Stock $stek

2023 Q1 Form 10-Q Financial Statement

#000168316823003420 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK
Stemtech Corp Stock $stek